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Stroke is the second most common cause of death in people over 45 years of age in Colombia and is the leading
cause of permanent disability worldwide. Cerebral ischemia is a stroke characterized by decreased blood flow due
to the occlusion of one or more cerebral arteries, which can cause memory problems and hemiplegia or paralysis,
among other impairments. The literature contains hundreds of therapies (invasive and noninvasive) that exhibit a
neuroprotective effect when evaluated in animal models. However, in clinical trials, most of these drugs do not
reproduce the previously demonstrated neuroprotective property, and some even have adverse effects that had
not previously been detected in animal experimentation.
Statins are drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting
enzyme in cholesterol synthesis. Several studies have shown that statin therapy in an animal model of focal cerebral
ischemia reduces infarct volume, as well as markers of neurodegeneration, activates neuronal survival pathways,
and improves performance on learning and memory tests. Given the implied therapeutic benefit and the limited
understanding of the mechanism of action of statins in brain repair, it is necessary to address the biochemical
and tissue effects of these drugs on synaptic proteins, such as NMDA receptors, synaptic adhesion proteins, and
cytoskeletal proteins; these proteins are highly relevant therapeutic targets, which, in addition to giving a structural
account of synaptic connectivity and function, are also indicators of cellular communication and the integrity of the
blood–brain barrier, which are widely affected in the long term post-cerebral infarct but, interestingly, are protected
by statins when administered during the acute phase.
Keywords: Cerebral ischemia, Statins, Synaptic proteins, Synaptic plasticity, Post-infarct protectionIntroduction
Stroke is the third leading cause of death in industrialized
countries [1] and the most common cause of disability in
adults worldwide [2]. In Latin America, the main causes of
the risk of death are cardiovascular accidents and stroke
due to a sedentary lifestyle, diabetes, atherosclerosis,
smoking, and hypertension. These diseases also increase
the risk of developing neurodegenerative diseases, such
as Alzheimer and vascular dementia [3].
Industrialized countries have turned their interest to the
aforementioned health issues as increasing life expectancy
has made them more prevalent in most of the world, be-
coming the silent epidemic of the current millennium. De-
veloping countries are also increasing their life expectancy,* Correspondence: patricia.cardonag@udea.edu.co
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article, unless otherwise stated.and this disorder is beginning to become a public health
problem with few current alternatives for healing.Cerebral ischemia
Cerebral ischemia is a type of stroke characterized by a
transient or permanent reduction in blood flow due to
embolic or thrombotic occlusion of one or more cerebral
arteries [4,5]. Depending on the duration of the reduced
blood flow and infarct location, cerebral ischemia can
cause various clinical manifestations, including paralysis
or hemiplegia, aphasia, and deficits in learning and mem-
ory processes, among other clinical manifestations [6].
If blood vessels that supply blood to all or most of the
brain become clogged, the injury is called global ischemia,
which usually happens during a heart attack or severe sys-
temic hypotension [7]. However, if only the occlusion of
vessels supplying blood to a certain area of the brain oc-
curs, a focal ischemia is generated [8]. Approximately 80%d Central. This is an Open Access article distributed under the terms of the
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middle cerebral artery (MCA) [9].
In focal ischemia, the region that suffers the most se-
vere degree of hypoperfusion progresses rapidly towards
irreversible damage due to a necrotic death, which rep-
resents the ischemic core. This area exhibits low cerebral
blood flow (<10% of the baseline value) and the irrevers-
ible failure of energy metabolism [10]. The remaining
hypoperfused tissue surrounding the ischemic core has
an imbalance in the mechanisms of the autoregulation
of blood flow and is known as the penumbra zone [11,12].
In this region, neurons show alterations in functionality,
although they retain a minimum metabolic activity that
preserves structural integrity for a longer period of time,
following a pattern of apoptotic death (Figure 1A) [13,14].
The penumbra is potentially recoverable and, as such, rep-
resents a key target for therapeutic intervention in cere-
bral ischemia [15]; however, unless perfusion is improved
or the cells become relatively resistant to the injury, the
cells of the penumbra zone are at risk of dying within a
few hours by necrosis [10,16].
Excitotoxicity in cerebral ischemia
The interruption of blood flow into the brain due to ische-
mia results in the deprivation of oxygen and glucose, redu-
cing the energy available for the operation of brain cells
[8]. Neurons in particular become unable to maintain the
ion gradients needed for cell function and homeostasis
[17], which results in excessive neuronal depolarization,
increased release of excitatory neurotransmitters, and re-
duced capacity of the reuptake of these neurotransmitters
by astrocytes. The overloading of glutamate, the main
excitatory neurotransmitter in the central nervous sys-
tem (CNS) of mammals, leads to prolonged stimulation
of AMPA ionotropic glutamate receptors (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA
receptors (N-methyl-D-aspartic acid), dramatically in-
creasing the influx of calcium (Ca2+), sodium (Na+), po-
tassium (K+), and water into the neurons [18]. Excessive
accumulation of ions and the simultaneous dysregulation
of various signaling pathways activate catabolic processes
mediated by proteases, lipases, and nucleases, which dis-
rupt neuronal function and lead to cell death [8,17].
Cerebral ischemia and alteration of synaptic
proteins
Ionotropic Receptors
After the establishment of neuronal connections during
development, the synapse remains highly dynamic and
undergoes changes in morphology and efficiency, which
are dependent on activity. The presynaptic terminal in-
cludes the machinery for neurotransmitter release, while
post-synaptic sites include proteins such as neurotrans-
mitter receptors and signaling proteins that promote theresponse to the released neurotransmitter, which allows
the transmission of information (Figures 1B, 2A) [19,20].
Among neurotransmitter receptors, NMDA receptors
have been extensively studied because they represent the
largest subclass of glutamate receptors in mammalian
excitatory synapses. They consist of four subunits, two
of which are NR1 combined with NR2 (NR2A-D) or NR3
(NR3A-B) subunits [21]. These receptors play a central
role in synaptic transmission, neuronal plasticity, regula-
tion of neuronal development, and connectivity, as well as
in memory and learning processes, primarily due to their
permeability to Ca2+ [22-24].
Located at the synapses, the NMDA receptors are not
static proteins; in fact, the number and composition of
NMDA receptors can be modified, which provides a dy-
namic mechanism for the regulation of synaptic efficacy
and remodeling [25]. Different regions of the receptor,
as well as scaffold proteins, such as PSD-95, and other
proteins of the postsynaptic density, all participate in the
mechanisms of internalization of NMDA. NMDA recep-
tors that bind to PSD-95 are stable in the membrane and
are less likely to be internalized (Figures 1B, 2A), while re-
ceptors that are not bound to proteins of the postsynaptic
density can be readily internalized. This mechanism can
“remove” from the membrane surface NMDA receptors
that are not permanent at the synapse [26].
The overactivation of NMDA receptors in cerebral is-
chemia induces excitotoxic cell death. Excessive activation
of NMDA induces a rapid and specific transcriptional in-
hibition of the NR1 subunit promoter in a process that is
strictly dependent on Ca2+ influx through the receptor.
NR1 transcriptional inhibition results in a progressive
reduction of its mRNA, which leads to a progressive re-
duction of the protein [27]. Overstimulation of NMDA
receptors can lead to a progressive decline in receptor
activity because its functionality depends strictly on the
expression of hetero-oligomers NR1/NR2 on the cell
surface [28].
Studies have shown that NR2A and NR2B subunits play
different roles in excitotoxic cell death [29]. While inhib-
ition of NR2B induces cell death and prevents motor and
cognitive recovery [30], inhibition of the NR2A subunit
leads to cell survival in a model of cerebral ischemia [29].
In models of excitotoxicity, it has been seen that excessive
activation of the NMDA receptors leads to increased intra-
cellular calcium, which results in the activation of calpain,
a protease that mediates cellular toxicity [31,32]. This pro-
tease efficiently cuts the C-terminal region of the NR2A
and NR2B subunit, producing truncated subunits that lack
certain sequences near serine-1303, which are critical to
the formation of signaling complexes in the postsynaptic
membrane [33]. The end result is the uncoupling of
NMDA receptors from scaffolding proteins, such as PSD-
95 (Figures 1C, 2B), affecting synaptic function [32].
Figure 1 (See legend on next page.)
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Figure 1 Neurodegeneration and protection in a focal cerebral ischemia model in rats. A) Histopathology of focal cerebral ischemia (tMCAO)
model in rats. a) Panoramic representative image of a whole rat brain with tMCAO injury. b) Contralateral and ipsilateral images from cerebral
ischemic rat tissue with Hematoxilin-eosin staining at the −3,80 mm bregma. LH = left hemisphere, RH = Right hemisphere, square = Selected area
from CA1 area. Scale bar = 1,7 mm. c), d), e) Left side representative images from Sham rats and Right side representative images from ischemic
rats. c) Hematoxilin-eosin staining 100x from CA1 square in b). Scale bar = 50 μm. d) Hyperphosphorylated tau immunoreactivity (AT-8) staining
40X in CA1 area. Scale bar = 70 μm. e) Fluorojade staining 10x. Scale bar = 100 μm. B), C) and D) Comparative hypothetical model of synaptic
proteins alteration following cerebral ischemia and Atorvastatin treatment. B) Sham, C) Ischemia and D) ATV-treated ischemia. B) Synaptic
complexes formed by proteins of synaptic adhesion (cadherins and catenins), glutamate receptors, and scaffold proteins, such as PSD-95 are
associated in a normal condition (Sh = Sham). C) Glutamate receptors are uncoupled from PSD-95 and are accumulated in the cytoplasm due to
retention of subunits in the endoplasmic reticulum (ER) because of the loss of transport toward synapses due to the alteration of microtubules
and the cytoskeleton. Proteins that regulate the cytoskeleton, such as RhoA increased and synaptic complexes formed by the complex cadherins/
catenins, glutamate receptors, and post-synaptic proteins, such as PSD-95 are lost. D) Model of protection by statins after cerebral ischemia.
Synaptic complexes formed by proteins of synaptic adhesion (cadherins and catenins), glutamate receptors, and scaffold proteins, such as PSD-95
are restored in synapse, inducing neuronal connectivity. ISCH= Ischemia, ATV = Atorvastatin.
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subunits of NMDA receptors are expressed in the cyto-
plasm following ischemia [30], which may be related to a
deficiency in the assembly of the different subunits mak-
ing up the receiver and/or problems in the transport
from the receptor to the synapses (Figure 1C). In the
knockout mouse for NR1, both reduction in the dendritic
distribution and accumulation in the cytoplasm of the
NR2B subunit [34] are observed, perhaps because of the
loss of the assembly of functional NMDA receptors to
the synaptic membrane or because NMDA receptors with
NR2B subunits located in the synaptic density are inter-
nalized by endocytosis to perform autoregulation and
avoid the continuous influx of calcium. It is known that
clathrin-mediated endocytosis is a mechanism that reg-
ulates the synaptic expression of NMDA receptors con-
taining NR2B during synaptic maturation in processes
such as long-term potentiation (LTP) or long-term de-
pression (LTD) as well as in response to a ligand [35].
Cytoskeletal proteins and cell adhesion
Transport from the receptor to and from synaptic sites
may be lost due to alteration of the microtubules and
damage to the actin cytoskeleton [36] (Figure 1C),
microtubule-associated proteins (MAP2) involved in the
regulation of vesicle transport during development or
regeneration of neuronal processes [37]. Our work and
other previous studies have found that these proteins
are redistributed in the soma after the acute post-ischemia
period [38,39], which is considered an indicator of excito-
toxic damage and loss of microtubule stability [38,39]
(Figure 1C). The actin cytoskeleton is primarily mediated
by the Rho GTPases, proteins that regulate its mainten-
ance, remodeling, and stability [40]. The RhoA and Rac1
proteins are among the most studied of the Rho GTPases.
In general terms, RhoA regulates actin assembly associ-
ated with processes of cellular shrinkage due to stress
[41,42], while Rac regulates actin polymerization, which is
related to axonal growth and stability and the increase ofdendritic processes [41,43]. Our research shows that RhoA
activity is increased in excitotoxic death processes [44]
(Figures 1C, 2B), and inhibiting this activity reduces
markers of neurodegeneration as well as improves
learning and memory processes in cerebral ischemia
[45]. Complementarily, in the acute post-ischemia period
(24 hours), Rac1 activity decreases and this protein is
redistributed in the soma and in aberrant neuronal pro-
cesses, which forms part of the process of chronic neuro-
degeneration [38].
Disassembly of the cytoskeleton in cerebral ischemia
mediated by RhoA activation and inactivation of Rac is
associated with the disruption of synaptic adhesion me-
diated by the complex of cadherin/catenins and [40],
proteins that are present in both presynaptic and postsyn-
aptic sites. Cadherins promote cell adhesion, and their
association with catenins allows the control of different
intracellular signaling pathways [19,46,47]. Structurally,
cadherins have an extracellular domain comprising most
of the polypeptide chain, generally composed of five repe-
titions, four of which are capable of binding extracellular
calcium. This extracellular domain mediates calcium-
dependent homophilic interactions with cadherins of
adjacent neurons. The cytoplasmic region includes the
binding sites to a variety of proteins, including catenins
[48]. Catenins are cytosolic proteins that are basically
subdivided into three groups: β-catenin, α N-catenin,
and p120 catenin (p120 ctn). The distal region of the
cadherin’s cytoplasmic domain includes the binding site
for β-catenin, while the nearest region to the membrane
contains the binding site for family members of p120
ctn. The protein α N-catenin binds to the complex by
binding with β-catenin [19].
In our recent studies using a model of focal ischemia in
rats, the levels of N-cadherin, p120 catenin, and ∝N ca-
tenin in the cerebral cortex and hippocampus were signifi-
cantly reduced, as was their association with PSD-95 and
glutamate receptors (NMDA and AMPA) (Figures 1C,
2B), which represents the loss of synaptic adhesion and of
Figure 2 Schematic representations of cell signalling alteration following cerebral ischemia and Atorvastatin treatment. A) Sham, B) Ischemia and C) ATV-
treated ischemia. A) NMDA receptors, synaptic adhesion proteins and PSD-95 are associated in the synapse. The stability of the actin cytoskeleton is
regulated by the RhoGTPasas (Rac, RhoA) balance and microtubules by protein such as MAP2. B) After cerebral ischemia cell adhesion is lost by alteration
in the cadherin-catenin complex; NMDA receptors and PSD-95 protein are distributed to the cytoplasm. The increased activity of RhoA, destabilizes actin
cytoskeleton and GSK3b activation leads to tau hyperphosphorylation disassembling microtubules. C) Treatment with atorvastatin recovers the adhesion
protein complex as well as the location NMDA receptor synapses associated to PSD-95. Additionally atorvastatin leads to AKT activation promoting cell
survival. Recovery of the actin cytoskeleton is mediated by the increased activity of Rac and RhoA reduction, and finally atorvastatin stabilize microtubules.
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itionally, there was an interdependence between Rac activ-
ity and the ∝N catenin distribution in dendrites, which
was lost in the event of glutamate excitotoxicity in primary
neuronal cultures [49].
Glycogen synthase kinase-3β (GSK-3β) is an essential
protein downstream of Akt that is involved in the patho-
logical process of brain damage. The PI3K/Akt signal
transduction pathway may affect the activity of GSK-3β.
Active Akt inhibits GSK-3β activity via phosphorylation
[50]. Sustained activation of GSK-3β is pro-apoptotic in
cerebral ischemia, because this leads to hyperphosphory-
lation of tau, microtubule destabilization (Figure 2B) and
cognitive impairment.
The foregoing are some of the cellular and biochem-
ical events underlying the impairment and neuronal
death after cerebral ischemia; however, it is important to
understand the precise mechanisms of the proteins
involved in the synapse, and their implication in mor-
phological and functional recovery. Such knowledge is
invaluable in the development of effective neuroprotec-
tive strategies to achieve an improved clinical outcome,
which results not only in survival but also in a higher
quality of life for patients who suffer acute cerebrovascu-
lar events, and to reduce or prevent long-term physical
and mental consequences.
Statins as treatment after a cerebral ischemia
The pharmacological approach for inducing neuropro-
tection after an injury due to cerebral ischemia aims at
blocking signaling pathways that trigger cell death, to in-
duce synaptic connectivity, and functional recovery. The
main goal is to limit the devastating consequences of re-
duced blood flow in the penumbra zone induced by re-
perfusion [14,51].
Statins are the drugs of choice for the treatment of
hypercholesterolemia that lower low density lipoproteins
(LDL) and triglycerides [52]. The mechanism of action
of these drugs is via competitive and selective inhibition
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, the rate-limiting enzyme in cholesterol syn-
thesis because it is responsible for the conversion of 3-
hydroxy-3-methylglutaryl CoA to mevalonate, which is
a precursor of cholesterol [52,53]. Studies such as the
Heart Protection Study, in which statin therapy signifi-
cantly reduces the coronary mortality rate and inci-
dence of stroke, confirm the need for strict control of
the lipid profile to reduce the overall risk and the
mortality rate caused by cardiovascular diseases and
stroke [54]. Also, a recently completed clinical trial,
NCT02225834 in phase IV, used Atorvastatin as acute
stroke treatment to evaluate separate effects on immu-
noinflamatory markers and atherothorombosis; or a re-
cently terminated clinical trial, NCT01364220 in phaseIII, used Rosuvastatin on early window for preventing
recurrence of ischemic stroke.
However, in addition to their effect on the lipid
profile, statins are also credited with effects that are in-
dependent of the reduction of cholesterol synthesis,
called pleiotropic effects. By inhibiting the conversion of
hydroxy-methylglutaryl Coenzyme A (HMG-CoA) to L-
mevalonate, statins block the synthesis of important
isoprenoids, such as farnesyl pyrophosphate (FPP) and
geranylgeranyl pyrophosphate (GGPP), which are import-
ant intermediates for the post-translational modification
of Rho GTPases (RhoA, Rac, and Cdc42) [53]. Among the
pleiotropic effects reported in cerebral ischemia are the im-
provement of endothelial function, the stability of the ath-
erosclerotic plaque, the attenuation of oxidative stress and
inflammation, and the inhibition of the thrombogenic re-
sponse [53]. Previous studies conducted on cerebral ische-
mia showed that statins improve neurological function
and increase cerebral blood flow [55-57], mitigating the
effects of inflammation and post-traumatic hypoperfusion
[53], in addition to protecting blood vessels and promot-
ing the processes of angiogenesis, neurogenesis, and syn-
aptogenesis after cerebral ischemia [58].
Using an embolic model, simvastatin-treated rats showed
a significant infarct volume reduction and neurological im-
provement compared to vehicle-treated group. Analyzing
their homogenated brains by two-dimensional fluorescence
Difference in Gel Electrophoresis (DIGE) technology, ob-
served that the protective effect of simvastatin can be
attributable to oxidative stress response attenuation and
blood–brain barrier protection after cerebral ischemia [59].
There are some additional evidences in humans, where the
treatment with statins is not only associated to a reduced
incidence of stroke but with reduced stroke severity, as
well [60]. In a small pilot trial with simvastatin in acute is-
chemic stroke (AIS), Montaner et al. showed more cases of
complete functional recovery after 3 months of treatment
with simvastatin (40 mg/day) in comparison with the non-
treated group (p < 0.05). The significant improvement was
observed on the third day of treatment [61].
A study by Kawashima et al. showed that cerivastatin
reduce the stroke-associated infiltration of inflammatory
cells, superoxide production in the cerebral parenchyma,
and cerebral damage caused by stroke, as well as delay
the appearance of stroke-associated symptoms and death
in stroke-prone, spontaneously hypertensive rats [62]. Re-
cently, we found that atorvastatin treatment increases the
expression of brain-derived neurotrophic factor (BDNF)
in an NR2B-dependent manner [30]; this trophic factor is
involved in survival [63] and is correlated with motor re-
covery and with spatial learning and memory (29). We
also confirmed that statins activate the PI3K/Akt pathway
(Figure 2C) and Ras/Erk, which transduce survival signals
and in turn promote synaptic plasticity [44].
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In an experimental model of focal cerebral ischemia, we
describe that in addition to neurological recovery and
the reduction of infarct volume and of neurodegeneration
markers, statin therapy during the acute post-ischemia
phase achieves the restoration of proteins involved in neur-
onal connectivity, such as NMDA receptors [30], synaptic
adhesion proteins (cadherins and catenins) and cytoskeletal
proteins (RhoA and Rac) [44]. Atorvastatin restores the
levels of N-cadherin, p120 catenin and ∝N catenin protein
in the cerebral cortex and in the hippocampus along with
the association of this complex of cadherins/catenins with
the PSD-95 protein (Figure 1D) [44]. These findings
support the restoration of synaptic complexes in cerebral
ischemia following statin therapy. Additionally, we have
found that atorvastatin treatment prevents the cytoplas-
mic distribution of subunits of glutamate receptors (NR1,
NR2B NMDA) and recovers their association with PSD-
95 and with proteins of synaptic adhesion (Figure 1D)
[30]. The latter is related to the recovery of microtubule
stability due to statin therapy, as MAP2 immunoreactivity
is restored both in the somatosensory cortex and in the
hippocampus [30,44], enabling the transport of the recep-
tors and their stability at the synapses (Figure 1 D). The
recovery of synaptic molecular complexes that involve
NMDA receptors and synaptic adhesion proteins is corre-
lated with a recovery of the motor and spatial learning
and memory deficits caused by ischemia [30].
Complementarily, we describe that atorvastatin post-
ischemia treatment tended to reduce RhoA activity which
leads to recovery the actin cytoskeleton (Figure 2C) [44].
By down-regulating Rho/Rho kinase signaling pathways,
statins increase the stability of eNOS mRNA and induce
activation of eNOS through phosphatidylinositol 3-kinase/
Akt/eNOS pathway restoring endothelial function [64].
The beneficial effects of Akt activation are not limited to
eNOS phoshorylation but extend to the promotion of sur-
vival neuronal (Figure 2C).Perspective
It is becoming necessary to advance both theoretically
and experimentally in the study of the factors involved
in cerebral ischemia and in the rigorous evaluation of
the drugs to be used and, with these results, to be able
to impact more precisely a population at increased risk
of suffering stroke. The purpose is to prevent, block, or
meet the needs of the affected community not only in
the short-term but also in the medium- and long-term
post-cerebral infarct period. This development must be
accompanied by training and improving the expertise
necessary for diagnosis and for making decisions in clin-
ical treatment inside and outside the therapeutic window
as well as by prevention programs designed to reduceneurodegenerative disorders in general and to improve
quality of life and access to health services.
According to the above, our work has specifically con-
tributed to elucidating the mechanisms of pathogenesis
and therapy in cerebral ischemia as well as to the under-
standing of the mechanisms and the cellular and molecular
targets of protection by statins. Our previous results and
the issues raised in this review allow us to recommend
from preclinical study in rats that atorvastatin, a drug
already on the market for human consumption as a
treatment for hypercholesterolemia, could be used as a
protective treatment during the first 6 hours post-
ischemic infarct. Its administration for at least three
days and ideally longer, with attention to the patient’s
adherence to the drug and its quality, could potentially
reduce or prevent the medium- and long-term severity
of neurologic dysfunction and of emotional and cogni-
tive compromise in patients.
Conclusion
In summary, statin therapy after a cerebral infarct blocks
the spread of damage and helps to restore brain morph-
ology and functionality, at least based on the induction
of trophic factors such as BDNF and of cell adhesion
proteins that generate a platform for synaptic proteins,
such as PSD-95, and NMDA receptors to settle and gener-
ate synaptic connectivity, neurotransmission, and cogni-
tive and motor function recovery.
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